Literature DB >> 21342773

The myocardial protective effects of adenosine pretreatment in children undergoing cardiac surgery: a randomized controlled clinical trial.

Zhenxiao Jin1, Weixun Duan, Min Chen, Shiqiang Yu, Haopeng Zhang, Guanli Feng, Lize Xiong, Dinghua Yi.   

Abstract

OBJECTIVE: Adenosine pretreatment reduces injury caused by ischemia-reperfusion. To investigate the hypothesis that adenosine pretreatment would modulate injury induced by cardiopulmonary bypass (CPB) and myocardial ischemia/reperfusion, we conducted a randomized controlled trial on the effects of adenosine pretreatment in children undergoing surgery to repair congenital heart defects.
METHODS: Children undergoing surgery to repair congenital heart defects were randomized to adenosine pretreatment or control treatment. Adenosine pretreatment was performed by infusing a total of 2.45 mg kg⁻¹ of adenosine over 10 min. Serum troponin I was measured pre- and postoperatively. Multiple clinical parameters, including postoperative use of inotropic medicine and duration in the intensive care unit (ICU), were recorded.
RESULTS: A total of 82 patients were enrolled in the study. There were 42 control patients and 40 patients in the adenosine pretreatment group. The mean age and weight of the two groups were not significantly different, nor were cardiopulmonary bypass and cross-clamp times. There were no deaths and severe complications in both groups. The adenosine pretreatment protocol caused significant hypotension but had no significant effect on heart rate. One patient had severe tachycardia shortly after the adenosine pretreatment protocol was completed, and adenosine infusion was continued until CPB was started. Postoperative levels of serum troponin I were greater in the control patients than in the adenosine pretreatment group, indicating that the control group suffered greater myocardial injury. Control group patients required more postoperative inotropic agents than those in the adenosine pretreatment group at 0, 1, and 3 h, indicating that the adenosine pretreatment group had a better cardiac function. The adenosine pretreatment group also required significantly less time in the ICU than the control group (3.2 ± 1.2 days vs 3.9 ± 1.2 days, p = 0.013).
CONCLUSIONS: This study demonstrates that adenosine pretreatment is protective of the myocardium during open-heart surgery in pediatric patients.
Copyright © 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21342773     DOI: 10.1016/j.ejcts.2010.12.052

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  Calcineurin and its regulator, RCAN1, confer time-of-day changes in susceptibility of the heart to ischemia/reperfusion.

Authors:  David Rotter; D Bennett Grinsfelder; Valentina Parra; Zully Pedrozo; Sarvjeet Singh; Nita Sachan; Beverly A Rothermel
Journal:  J Mol Cell Cardiol       Date:  2014-05-15       Impact factor: 5.000

Review 2.  Protein kinase C, an elusive therapeutic target?

Authors:  Daria Mochly-Rosen; Kanad Das; Kevin V Grimes
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

3.  Adenosine Preconditioning versus Ischemic Preconditioning in Patients undergoing Off-Pump Coronary Artery Bypass (OPCAB).

Authors:  Seyed Khalil Forouzannia; Mohammad Hassan Abdollahi; Seyed Jalil Mirhosseini; Mehdi Hadadzadeh; Rouholla Zarepur; Ehsan Zarepur; Omid Beiki; Mohammadtaghi Sarebanhassanabadi
Journal:  J Tehran Heart Cent       Date:  2013-07-30

4.  Protein kinase C beta II suppresses colorectal cancer by regulating IGF-1 mediated cell survival.

Authors:  Catríona M Dowling; James Phelan; Julia A Callender; Mary Clare Cathcart; Brian Mehigan; Paul McCormick; Tara Dalton; John C Coffey; Alexandra C Newton; Jacintha O'Sullivan; Patrick A Kiely
Journal:  Oncotarget       Date:  2016-04-12

Review 5.  Protein kinase C and cardiac dysfunction: a review.

Authors:  Raphael M Singh; Emanuel Cummings; Constantinos Pantos; Jaipaul Singh
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 6.  Adenosine at the Interphase of Hypoxia and Inflammation in Lung Injury.

Authors:  Xiangyun Li; Nathanial K Berg; Tingting Mills; Kaiying Zhang; Holger K Eltzschig; Xiaoyi Yuan
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

Review 7.  Role and Mechanism of PKC-δ for Cardiovascular Disease: Current Status and Perspective.

Authors:  Li-Na Miao; Deng Pan; Junhe Shi; Jian-Peng Du; Peng-Fei Chen; Jie Gao; Yanqiao Yu; Da-Zhuo Shi; Ming Guo
Journal:  Front Cardiovasc Med       Date:  2022-02-15

Review 8.  Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: a review.

Authors:  Katarzyna Kolczynska; Angel Loza-Valdes; Izabela Hawro; Grzegorz Sumara
Journal:  Lipids Health Dis       Date:  2020-05-28       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.